Bevacizumab, a monoclonal antibody targeted to vascular endothelial growth factor A (VEGF-A), has been shown to offer some progression-free survival benefits in patients who develop recurrent glioblastoma (10). The gene discussed is VEGFA; the disease is glioblastoma.